Scarica l'app Stockscreener
6.52
1.79%
-0.18
Precedente Chiudi:
$6.70
Aprire:
$6.58
Volume 24 ore:
1,856
Relative Volume:
0.00
Capitalizzazione di mercato:
$84.08M
Reddito:
$200.00K
Utile/perdita netta:
$-26.17M
Rapporto P/E:
-2.51
EPS:
-2.5976
Flusso di cassa netto:
$-18.63M
1 W Prestazione:
+2.98%
1M Prestazione:
+11.17%
6M Prestazione:
-35.27%
1 anno Prestazione:
+177.22%
Intervallo 1D:
$6.58
$6.58
Intervallo di 1 settimana:
$6.3187
$6.93
Portata 52W:
$2.36
$13.50
Clene Inc Stock (CLNN) Company Profile
Nome
Clene Inc
Settore
Industria
Telefono
801-676-9695
Indirizzo
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
6.58 | 85.61M | 200.00K | -26.17M | -18.63M | -2.5976 |
VRTX
Vertex Pharmaceuticals Inc
|
435.39 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.24 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.98 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.80 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.60 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-02 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-28 | Iniziato | Oppenheimer | Outperform |
Clene Inc Borsa (CLNN) Ultime notizie
CLNN stock falls after Roth labels accelerated approval for ALS drug a 'long shot' - MSN
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Files Form 8-K with SEC Detailing Company Information and Common Stock Listing on NASDAQ - Minichart
Clene extends note maturity and amends stock plan following annual meeting - Investing.com
Clene Extends 2025 Convertible Notes to 2027, Defers $150,000 Monthly Payments - TradingView
Clene (NASDAQ: CLNN) extends convertible note maturity and adds 1M plan shares - Stock Titan
Clene (NASDAQ: CLNN) director granted 3,564 stock options at $6.81 exercise price - Stock Titan
Clene Inc. (NASDAQ: CLNN) director receives 3,658 stock options at $6.81 strike - Stock Titan
Clene (NASDAQ: CLNN) director awarded 4,361 stock options at $6.81 strike - Stock Titan
Clene Inc. (CLNN) director granted 5,159 stock options as equity compensation - Stock Titan
Clene (CLNN) director granted 4,291-share stock option package - Stock Titan
[Form 4] Clene Inc. Insider Trading Activity - Stock Titan
Clene (NASDAQ: CLNN) director Jonathon Gay receives 3,728 stock options at $6.81 - Stock Titan
Clene (CLNN) awards director two stock option grants at $6.81 - Stock Titan
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? - Yahoo Finance
CLNN News | CLENE INC (NASDAQ:CLNN) - ChartMill
Clene Inc. (CLNN) reports Q1 loss, misses revenue estimates - MSN
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Clene (CLNN) Gets a Buy from JonesTrading - The Globe and Mail
Is Clene (CLNN) Overvalued After Q1 2026? EPS -$0.69 Misses Est. - GuruFocus
JonesTrading Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
A Quick Look at Today's Ratings for Clene(CLNN.US), With a Forecast Between $30 to $50 - Moomoo
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Chidozie Ugwumba reports 9.7% stake in Clene Inc. (CLNN) - Stock Titan
Clene (CLNN) Receives Positive Analyst Rating and Funding Outloo - GuruFocus
Clene Inc. (NASDAQ: CLNN) insider reports 1.83M shares, 13% - Stock Titan
Clene Reports Q1 2026 Loss Amid Positive Regulatory News for CNM-Au8 - GuruFocus
Chidozie Ugwumba reports 1.92M Clene shares (NASDAQ: CLNN) 14.8% - Stock Titan
Clene Inc. 2026 Q1 Financial Results, Risk Factors, and Forward-Looking Statements – Quarterly Report Highlights - Minichart
Clene Releases Q1 2026 Financial Results - AlphaStreet
Clene (CLNN) Reports Q1 Revenue and Progress on ALS Treatment - GuruFocus
Clene Inc. Reports Q1 2026 Financial Results and Advances CNM-Au8 for ALS FDA Approval - Minichart
Clene 3Q Rev $15,000 >CLNN - Moomoo
Clene Expects to Submit NDA for CNM-Au8 Under the Accelerated Approval Pathway in 3Q >CLNN - Moomoo
Clene 3Q Loss/Shr 69c >CLNN - Moomoo
Clene Sees Operating Runway Into 4Q of 2026 - Moomoo
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights - Investing News Network
Clene IncEnters second amendment to senior secured convertible notesSEC filing - marketscreener.com
Clene Extends Debt Maturities and Strengthens Cash Runway - TipRanks
Clene (NASDAQ: CLNN) readies ALS NDA as Q1 loss deepens and cash runway extends - Stock Titan
Experimental ALS drug moves toward FDA filing as Clene shores up cash - Stock Titan
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Clene Inc. (CLNN) posts larger Q1 2026 loss and flags going concern - Stock Titan
Clene Insider Sold Shares Worth $604,130, According to a Recent SEC Filing - Moomoo
Clene Inc Azioni (CLNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Clene Inc Azioni (CLNN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
0.67%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):